| 9.37 0.43 (4.81%) | 08-04 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 13.01 |
1-year : | 15.19 |
| Resists | First : | 11.14 |
Second : | 13.01 |
| Pivot price | 8.06 |
|||
| Supports | First : | 8.71 |
Second : | 7.21 |
| MAs | MA(5) : | 8.42 |
MA(20) : | 8.35 |
| MA(100) : | 8.17 |
MA(250) : | 9.54  |
|
| MACD | MACD : | -0.2 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 75.2 |
D(3) : | 53 |
| RSI | RSI(14): 60.3 |
|||
| 52-week | High : | 17.57 | Low : | 5.36 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ DNA ] has closed Bollinger Bands are 13.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.43 - 9.47 | 9.47 - 9.5 |
| Low: | 8.82 - 8.86 | 8.86 - 8.9 |
| Close: | 9.3 - 9.37 | 9.37 - 9.43 |
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Fri, 31 Jul 2026
Ginkgo Bioworks Holdings Inc (DNA) Institutional Confidence - TradingKey
Fri, 31 Jul 2026
DNA|Ginkgo Bioworks Holdings Inc|Price:8.090|Chg%:-0.010 - TradingKey
Thu, 30 Jul 2026
Ginkgo Bioworks (NYSE: DNA) awards RSUs to 10% owner - Stock Titan
Thu, 30 Jul 2026
Ginkgo Bioworks (NYSE: DNA) plans Q2 2026 results presentation and Q&A - Stock Titan
Thu, 09 Jul 2026
Ginkgo Bioworks Holdings' Stock Sinks To US$9.07, But Insiders Sold Even Lower - simplywall.st
Fri, 22 May 2026
Ginkgo Bioworks Holdings Inc (DNA): What’s the Future of Autonomous Lab? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 4.5 (%) |
| Held by Institutions | 68.7 (%) |
| Shares Short | 5,210 (K) |
| Shares Short P.Month | 4,910 (K) |
| EPS | -5.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.19 |
| Profit Margin | -201.1 % |
| Operating Margin | -366.6 % |
| Return on Assets (ttm) | -16.2 % |
| Return on Equity (ttm) | -56.1 % |
| Qtrly Rev. Growth | -49.1 % |
| Gross Profit (p.s.) | 1.97 |
| Sales Per Share | 2.83 |
| EBITDA (p.s.) | -4.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -166 (M) |
| Levered Free Cash Flow | -78 (M) |
| PE Ratio | -1.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.3 |
| Price to Sales | 3.3 |
| Price to Cash Flow | -3.01 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|